| Species |
Human
|
| Cat.No |
ABC-KH034Y
|
| Quality Control |
All cells test negative for mycoplasma, bacteria, yeast, and fungi.
|
| Product Category |
Transfected Stable Cell Lines |
| Size/Quantity |
1 vial
|
| Cell Type |
Epithelial
|
| Shipping Info |
Dry Ice
|
| Growth Conditions |
37 ℃, 5% CO2
|
| Source Organ |
Skin
|
| Disease |
Epidermoid Cancer
|
| Biosafety Level |
1
|
| Storage |
Liquid Nitrogen
|
| Product Type |
Knockout Stable Cell Line
|
| Host Cell |
A-431
|
| Gene Info |
IL1RN
|
Description
Human IL1RN Knockout A-431 Cell Line is engineered from human epidermoid carcinoma A-431 cells using CRISPR/Cas9 technology to disrupt the Interleukin 1 Receptor Antagonist (IL1RN) gene, a natural inhibitor of pro-inflammatory IL-1α and IL-1β signaling. This knockout model exhibits hyperactive IL-1-mediated inflammation and enhanced NFκB activation while maintaining A-431 cells’ characteristic adherent growth with epithelial morphology. The cell line provides a critical tool for studying inflammatory skin disorders, tumor microenvironment interactions, and psoriasis pathogenesis, particularly in research involving IL-1-driven cytokine cascades and epidermal barrier dysfunction. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through genomic PCR, Sanger sequencing, and functional assays demonstrating elevated IL-1β responsiveness. The cell line has undergone rigorous quality control and is certified free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.
